TY - JOUR T1 - Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3480 AU - Dinesh Saralaya AU - Andrew Menzies-Gow AU - Ian Clifton AU - Adel H. Mansur AU - Alan Hart-Thomas AU - Rob Niven Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3480.abstract N2 - A previous retrospective study of routine UK clinical practice demonstrated omalizumab improves lung function and reduces asthma exacerbations and oral corticosteroid (OCS) burden. The aim of this multicentre observational study was to confirm these findings prospectively. Retrospective data were collected in the 12 months prior to omalizumab initiation, while prospective data were collected at 16 weeks, 8 and 12 months following initiation. The primary endpoint was the change in mean daily OCS dosage (reported previously). Secondary endpoints included changes in mean exacerbations and lung function. 235 patients were enrolled in the study as at end of December 2013. Interim analysis data were for patients who had 12 months assessment of lung function. Average (16 week, 8 month, 12 month combined data) FEV1% predicted improved from 68.3 to 73.6 (n=84, p<0.01) in the 12 months pre and post omalizumab initiation respectively. Changes in mean FEV1 % at 16 weeks, 8 months and 12 months are reported in table 1.View this table:Changes in mean FEV1% predictedThis study confirms that omalizumab improved lung function. Statistically significant results were achieved at 16 weeks and 8 months. Statistical significance was not achieved at 12 months in this interim analysis. ER -